EntreMed's MKC-1 in Ph I study in leukemia patients
USA-based pharmaceutical company EntreMed says that it has initiated a Phase I study of its drug candidate MKC-1, a novel, orally-active inhibitor of mitotic spindle formation during cell division, in patients with hematological malignancies.
EntreMed said that its decision to examine the agent as a treatment for leukemia was based on the activity it demonstrated against a variety of cancerous hematological cells lines in preclinical studies. In addition, the firm reported that the drug has not been linked to any neuropathy or cardiotoxicity in trials completed so far.
Carolyn Sidor, EntreMed's vice president and chief medical officer, said: "initiation of this clinical trial represents continued progress on our clinical development plan for MKC-1." She added that the agent is also currently in a Phase II trial in patients with metastatic breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze